摘要
目的观察西酞普兰与氯米帕明对躯体化障碍的疗效和不良反应。方法将躯体化障碍患者66例随机分为治疗组和对照组各33例,治疗组给予西酞普兰,从20 mg.d-1开始,根据病情需要调整剂量,最大至40 mg.d-1;对照组给予氯米帕明,从25 mg.d-1开始,第3天加到75 mg.d-1,根据需要调整剂量,最大至150 mg.d-1。治疗8周,用症状自评量表(SCL-90)、临床疗效大体评定量表(CG I)评价疗效,用不良反应量表(TESS)评价不良反应。结果治疗8周后,治疗组和对照组总有效率分别为93.6%,86.2%(Χ2=0.276,P>0.05)。治疗组起效快,不良反应较小。结论西酞普兰与氯米帕明对躯体化障碍的治疗均有效;西酞普兰起效较快、不良反应小,可以作为躯体化障碍治疗的首选药物之一。
Objective To assess the efficacy and adverse-effects of citalopram and chlorimipramine in the treatment of somatization disorder. Methods Sixty-six patients with somatization disorder were randomly allocated to two groups with citalopram 20 - 40 mg·d^-1 or chlorimipramine 25 - 75 mg ·d^-1 for 8 weeks. Symptom Checklist 90 （SCL-90） and Clinical Global Impression（CGI） were used to assess the efficacy. Treatment Emergent Symptom Scale （TESS） was used to assess the adverse-effects. Results After 8 weeks, citalopram and chloripramine had similar therapeutic efficacy, but citalopram showed efficacy earlier with fewer adverse-effects than chloripramine. Conclusion Both citalopram and chlorimipramine are effective in the treatment of somatization disorder. Citalopram has more rapid effect with fewer adverse-effects than chloripramine. So, citalopram can be used as a medicine of first choice for the treatment of somatization disorder.
出处
《医药导报》
CAS
2007年第3期264-266,共3页
Herald of Medicine
